Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-FIX in severe hemophilia B
NCT02695160Phase 1Terminated
- Sponsor
- Sangamo Therapeutics
- Start
- Nov 2016
- Primary completion
- Apr 2021
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of adlinacogene civaparvovec in hemophilia B (HB) (3 cohorts), sponsored by Sangamo Therapeutics. Primary endpoint: Number of Participants With Treatment Related Adverse Events at 36 months. Started Nov 2016; status: terminated.
02
Drugs
adlinacogene civaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02695160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695160.